Stock Events

Stock Events

Exicure 

€3.24
53
+€0.44+15.71% Monday 07:38

Statistics

Day High
3.24
Day Low
3.24
52W High
7.15
52W Low
1.48
Volume
-
Avg. Volume
-
Mkt Cap
20.65M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MarExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q3 2025
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-1,967.41%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
946,315Revenue
-18.62MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2H0.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, directly competing with Exicure's spherical nucleic acid (SNA) technology.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in antisense technology, which is a form of RNA-targeted therapy competing with Exicure's approach.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap5.86B
Arrowhead Pharmaceuticals develops drugs based on RNA interference, a similar field to Exicure's, making them direct competitors.
Moderna
MRNA
Mkt Cap10.61B
Moderna is known for mRNA technology, which, while different, competes in the broader space of nucleic acid therapies where Exicure operates.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE, although famous for its mRNA COVID-19 vaccine, works on nucleic acid technologies that compete with Exicure's SNA platform.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is focused on gene editing, a different but competing approach to treating diseases at the genetic level compared to Exicure.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the gene editing space with CRISPR technology, offering a competing approach to Exicure's genetic intervention strategies.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in CRISPR-based gene editing, competing in the broader market of genetic therapies against Exicure.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on RNA-targeted treatments, particularly for rare diseases, competing with Exicure's RNA-based therapeutic approaches.

About

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Show more...
CEO
ISIN
US30205M3097
WKN
000A40L5C

Listings

F
DE
2H0.F
XNAS
US
XCUR
BOATS
BOATS
XCUR.BOATS

0 Comments

Share your thoughts

FAQ

What is Exicure stock price today?▼
The current price of 2H0.F is €3.24 EUR — it has increased by +15.71% in the past 24 hours. Watch Exicure stock price performance more closely on the chart.
What is Exicure stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Exicure stocks are traded under the ticker 2H0.F.
What is Exicure market cap?▼
Today Exicure has the market capitalization of 20.65M
When is the next Exicure earnings date?▼
Exicure is going to release the next earnings report on March 18, 2026.
What is Exicure revenue for the last year?▼
Exicure revenue for the last year amounts to 946,315 EUR.
What is Exicure net income for the last year?▼
2H0.F net income for the last year is -18.62M EUR.
When did Exicure complete a stock split?▼
The last stock split for Exicure was on August 28, 2024 with a ratio of 1:5.